Related Experiment Video
Updated: Apr 15, 2026
Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
Identification of the neutralizing epitopes of Merkel cell polyomavirus major capsid protein within the BC and EF
Maxime J J Fleury1, Jérôme T J Nicol2, Mahtab Samimi3
1L'UNAM Université, Groupe d'Etude des Interactions Hôte-Pathogène, UPRES EA 3142, Université d'Angers, Angers, France.
Abstract:
Merkel cell polyomavirus (MCPyV) is the first polyomavirus clearly associated with a human cancer, i.e. the Merkel cell carcinoma (MCC). Polyomaviruses are small naked DNA viruses that induce a robust polyclonal antibody response against the major capsid protein (VP1). However, the polyomavirus VP1 capsid protein epitopes have not been identified to date. The aim of this study was to identify the neutralizing epitopes of the MCPyV capsid. For this goal, four VP1 mutants were generated by insertional mutagenesis in the BC, DE, EF and HI loops between amino acids 88-89, 150-151, 189-190, and 296-297, respectively. The reactivity of these mutants and wild-type VLPs was then investigated with anti-VP1 monoclonal antibodies and anti-MCPyV positive human sera. The findings together suggest that immunodominant conformational neutralizing epitopes are present at the surface of the MCPyV VLPs and are clustered within BC and EF loops.
Insights
Researchers identified key regions on the Merkel cell polyomavirus (MCPyV) capsid protein (VP1) that trigger a protective immune response. These findings advance understanding of MCPyV-associated Merkel cell carcinoma (MCC) and viral immunity.
Area of Science:
- Virology
- Immunology
- Oncology
Background:
- Merkel cell polyomavirus (MCPyV) is linked to Merkel cell carcinoma (MCC), a rare human cancer.
- Polyomaviruses elicit strong antibody responses against their major capsid protein (VP1).
- Neutralizing epitopes on the MCPyV VP1 protein remain unidentified.
Purpose of the Study:
- To identify the neutralizing epitopes on the MCPyV capsid protein (VP1).
Main Methods:
- Generated four VP1 mutants using insertional mutagenesis in specific loops (BC, DE, EF, HI).
- Tested mutant and wild-type virus-like particles (VLPs) for reactivity with monoclonal antibodies and human sera.
- Analyzed antibody binding to identify immunodominant regions.
Main Results:
- Immunodominant conformational neutralizing epitopes are located on the MCPyV VLP surface.
- These critical epitopes are primarily clustered within the BC and EF loops of the VP1 protein.
Conclusions:
- The study successfully mapped neutralizing epitopes on the MCPyV VP1.
- Identified epitopes are crucial for the virus's interaction with the immune system.
- Findings contribute to understanding MCPyV pathogenesis and potential therapeutic strategies for MCC.
